Thus we worked on the premise that targeting these aggressive self-renewing Bcr-Abl+ CD34+/CD38− hCSCs could be an effective strategy for the eradication of CML. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.